Trial reportJournal of substance abuse treatment
A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.
Trial report in Journal of substance abuse treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Extended-release injectable naltrexone for opioid use disorder: a systematic review.Addiction (Abingdon, England) · 2018Pooled it
- Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.Drug and alcohol dependence · 2021Trial
- A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.The American journal of psychiatry · 2019Trial
- Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.Drug and alcohol dependence · 2018Trial
- Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.Journal of substance abuse treatment · 2018Trial
- Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.The American journal of psychiatry · 2017Trial
- Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.Drug and alcohol dependence · 2015Trial
- The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.Drug and alcohol dependence · 2015Trial
- Baseline characteristics of patients predicting suitability for rapid naltrexone induction.The American journal on addictions · 2015Trial
- Memantine: updates from the past decade and implications for future novel therapeutic applications.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Managing Opioid Withdrawal Symptoms During the Fentanyl Crisis: A Review.Substance abuse and rehabilitation · 2024Review
- Transport of Maternally Administered Pharmaceutical Agents Across the Placental Barrier In Vitro.ACS applied bio materials · 2022Article
- Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.Drug and alcohol dependence · 2022Article
- Improving Translational Research Outcomes for Opioid Use Disorder Treatments.Current addiction reports · 2021Article
- Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.The American journal on addictions · 2018Review
- Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.Journal of substance abuse treatment · 2018Article
- Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults.Addiction (Abingdon, England) · 2017Article
- Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.Substance abuse · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
There is preclinical support for using NMDA receptor glutamatergic antagonists to aid in naltrexone-based treatment of opioid dependence. We hypothesized that adding memantine will improve efficacy of extended-release (XR) naltrexone to prevent relapse. In this double blind study opioid-dependent participants (N=82) underwent inpatient detoxification and naltrexone induction. During naltrexone initiation participants were randomized to receive memantine 40 mg or placebo and continued treatment for 12-weeks with XR naltrexone and relapse-prevention therapy. Sixty eight percent of participants completed detoxification and received the first dose of XR naltrexone. Rates of trial completion were significantly greater in participants receiving placebo than memantine (70% vs. 43%, p<0.05). Severity of opioid withdrawal symptoms during the first 3 weeks of the trial appeared to be lower in the group receiving memantine (p=0.07). Adding memantine does not appear to increase the effectiveness of injectable XR naltrexone as a relapse prevention strategy in opioid dependence and may lead to an increase in treatment drop-out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.